Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.

Jeffrey FranksNicole E CastonAhmed ElkhananyTravis GerkeAndres AzueroGabrielle Betty Rocque

Published in: Breast cancer research and treatment (2022)

Prior treatment duration and class are associated with a decreased overall survival after CDK 4/6 inhibitor administration. This highlights the importance for clinicians to consider prior treatment and duration in treatment decision-making and for trialists to stratify by these factors when randomizing patients or reporting results of future studies.

Keyphrases

end stage renal disease
decision making
emergency department
newly diagnosed
chronic kidney disease
cell cycle
palliative care
prognostic factors
peritoneal dialysis
free survival